|
Rasburicase
resources
|
|
|
|
|
|
DRUG INFO
Rasburicase
Drug Name:
Rasburicase
Indication: For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
Pharmacology: Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism Of Action: Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
Drug Category: Antihyperuricemic Agents; enzymes (44:00.00)
Brand Names/Synonyms: Uricase; Urate oxidase; Elitek (Sanofi-Synthelabo; Inc)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Aspergilus urate oxidase
Chemical Formula: C1521H2381N417O461S7
Half Life: 8 hrs
Drug Type: Approved Drug
# Accession No: BIOD00090
CAS Registry Number: 134774-45 1
|
|
|
|
|
|
Rasburicase News
(When available)
Update on Gout and Other Crystal-Induced Arthritides Jan 5, 2006
Medscape (subscription) Important clinical trials of uricase and febuxostat in the management of hyperuricemia and tophus reduction were presented at the 2005 ACR meeting. ...
Savient Pharmaceuticals Closes Sale of Delatestryl(R) Product to ... Jan 9, 2006
Genetic Engineering News, ...the execution of our strategy to concentrate our efforts going forward on the development of our lead product candidate Puricase(R) (PEG-uricase), which will ...
|
|
|
